Related Experiment Video
Updated: May 24, 2026

Spectral Confocal Imaging of Fluorescently tagged Nicotinic Receptors in Knock-in Mice with Chronic Nicotine Administration
Published on: February 10, 2012
A DRD2 and ANKK1 haplotype is associated with nicotine dependence
Joanne Voisey1, Christopher Dean Swagell, Ian Paul Hughes
1Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, Queensland, Australia. j.voisey@qut.edu.au
Genetic variations in the dopamine D2 receptor (DRD2) influence nicotine dependence. Specific DRD2 C957T and ANKK1 TaqIA gene variants significantly increase susceptibility to nicotine addiction.
Area of Science:
- Neuroscience
- Genetics
- Addiction Research
Background:
- Nicotine dependence is a complex condition with significant genetic underpinnings.
- The dopamine D2 receptor (DRD2) system plays a crucial role in reward pathways implicated in addiction.
Purpose of the Study:
- To investigate the association between specific dopamine D2 receptor (DRD2) gene polymorphisms and nicotine dependence.
- To determine the contribution of DRD2 C957T and ANKK1 TaqIA variants to genetic susceptibility for nicotine addiction.
Main Methods:
- Genotyping of 150 smokers and 228 controls for DRD2 C957T, -141delC, and ANKK1 TaqIA polymorphisms.
- Statistical analysis of allele, genotype, haplotype, and combined genotype associations with nicotine dependence.
Main Results:
- The DRD2 C957T and ANKK1 TaqIA polymorphisms showed significant associations with nicotine dependence at multiple levels.
- A specific haplotype (957C/TaqI A1) was strongly linked to nicotine dependence.
- Combined genotypes (DRD2 957 CC and ANKK1 TaqIA A1) significantly increased the likelihood of nicotine dependence, accounting for 13% of susceptibility.
Conclusions:
- The DRD2 C957T and ANKK1 TaqIA polymorphisms are key genetic contributors to nicotine dependence susceptibility.
- These findings highlight the role of the DRD2 pathway in the genetic basis of nicotine addiction.
Related Concept Videos
Drugs Acting on Autonomic Ganglia: Stimulants
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating sympathetic or...
Cholinergic Receptors: Nicotinic
There are two types of nicotinic receptors: neuromuscular (NM/NM/N1) and neuronal (NN/NN/N2). The two families differ based on their location and selectivity to...
Drug Dependence
Drug Abuse and Addiction: Pharmacological Phenomena
CNS Depressants: Alcohol and Nicotine
Exon Recombination
Exon shuffling follows “splice frame rules.” Each exon has three reading...

